Abstract 1487P
Background
Information and Communication Technology-based self-management support has been demonstrated to be effective in relieving symptoms for patients with advanced cancer. This study aimed to evaluate the effectiveness of a telemonitoring system for cancer pain relief in outpatients with advanced cancer in Japan.
Methods
The study was conducted between December 2019 and February 2023. This study included patients attending Tohoku University Hospital as outpatients, regularly taking opioids for cancer pain, with a mean pain NRS of ≥3 in 24 hours. Participants were randomized into intervention and control groups in a 1:1 ratio. The intervention group received telemonitoring care using the Cancer Pain Monitoring System (CAPAMOS). This comprises five components: symptom checks, medication checks, graphical records, pain booklet, and contact with a telenurse (chats, phones, and video phones). Alerts were sent to a telenurse when a patient’s symptoms worsened. The control group maintained a pain diary. An assessment of pain (NRS), quality of life (VAS), and opioid self-management scale (Opioid Self-Management Scale for Advanced Cancer Patients with Pain: OSSA) was conducted at baseline and after 2 and 4 weeks. Further, the Ethics Committee of Tohoku University Graduate School of Medicine reviewed the study (approval no. 2020-1-194).
Results
A total of 48 patients were enrolled in this study. There were no significant differences in baseline age (intervention 53.5 vs. control 57.0, p=0.68), severe pain (5.0 vs. 5.0, p=0.92), average pain (4.0 vs. 4.0, p=0.41), OSSA scores (135.0 vs. 130.0, p=0.06) and QOL (70.0 vs. 64.0, p=0.86) between groups. At 2 weeks post-intervention, no significant association was observed. At 1 month post-intervention, severe pain (5.0 vs. 5.5, p = 0.37), average pain (3.0, vs. 4.0, p = 0.41), OSSA scores (136.5 vs. 123.5, p=0.06), and QOL scores (57.5 vs. 50.0, p = 0.58) were not statistically significant. The scores for understanding pain characteristics in OSSA were significantly higher in the OSSA group than in the control group (10.0 vs. 8.0, p=0.04).
Conclusions
Telemonitoring support has led to educational advantages, such as improving patients’ understanding of opioid self-management and pain characteristics.
Clinical trial identification
UMIN000038334.
Editorial acknowledgement
Legal entity responsible for the study
Tohoku University Graduate School of Medicine.
Funding
JSPS KAKENHI.
Disclosure
All authors have declared no conflicts of interest.
Resources from the same session
1607P - Association of the lipid biomarker, PCPro, and clinical outcomes in the ENZAMET trial (ANZUP 1304)
Presenter: Lisa Horvath
Session: Poster session 10
1608P - Prostate cancer working group 4 (PCWG4) preliminary criteria using serial PSMA PET/CT for response evaluation: Analysis from the PRINCE trial
Presenter: Michael Hofman
Session: Poster session 10
1609P - PSMA-PET and PROMISE re-define stage and risk in patients with prostate cancer
Presenter: Wolfgang Fendler
Session: Poster session 10
1610P - Circulating tumour cell (CTC) enumeration and overall survival (OS) in men with metastatic castration-resistant prostate cancer (mCRPC) treated with xaluritamig
Presenter: Andrew Armstrong
Session: Poster session 10
1611P - Haematologic impact of [177Lu]Lu-PSMA-617 versus ARPI change in patients with metastatic castration-resistant prostate cancer in PSMAfore
Presenter: Kim Nguyen Chi
Session: Poster session 10
1612P - Impact of FANCA, ATM, CDK12 alterations on survival in metastatic castration-resistant prostate cancer (mCRPC)
Presenter: David Lorente
Session: Poster session 10
1613P - Clinically advanced prostate cancer (CAPC) featuring BRCA2 loss: A comprehensive genomic profiling (CGP) study
Presenter: Chiara Mercinelli
Session: Poster session 10
1614P - PSA responses and PSMA scan changes after immunotherapy for biochemically recurrent prostate cancer (BCR) without androgen deprivation therapy (ADT)
Presenter: Ravi Madan
Session: Poster session 10
1615P - A new prognostic model of overall survival (OS) in patients (pts) with metastatic hormone sensitive prostate cancer (mHSPC)
Presenter: Susan Halabi
Session: Poster session 10